Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis

Annals of Medicine

Volumn 36, Issue 3, 2004, Pages 194-203

  Wiedermann, Christian J ^a,b,c   Kaneider, Nicole C ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b CENTRAL HOSPITAL OF BOLZANO   (Italy)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Disseminated intravascular coagulation; Evidence based medicine; Infection; Inflammation

Indexed keywords

ACTIVATED PROTEIN C; ANTIINFECTIVE AGENT; ANTITHROMBIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12A; CATECHOLAMINE; CELL ADHESION MOLECULE; CORTISONE; CYTOKINE; DROTRECOGIN; DRUG RECEPTOR; HEPARIN; INSULIN; INTERLEUKIN 6; INTERLEUKIN 8; KALLIKREIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; SYNDECAN 4; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTIFICIAL VENTILATION; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ENDOTHELIUM; HEMOFILTRATION; HUMAN; INFLAMMATION; INSULIN TREATMENT; LOW DRUG DOSE; MORTALITY; NEISSERIA MENINGITIDIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN C DEFICIENCY; PROTEIN FUNCTION; REVIEW; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTITHROMBIN III; BLOOD COAGULATION; CLINICAL TRIALS; HUMANS; INFLAMMATION; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 2542451293     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890410027943     Document Type: Review

References (85)

1. Gross PL, Aird WC. The endothelium and thrombosis. Semin Thromb Hemost 2000;26:463-78.
2. Esmon CT, Protein C. pathway in sepsis. Ann Med 2002;34: 598-605.
3. Iba T, Kidokoro A, Yagi Y. The role of the endothelium in changes in procoagulant activity in sepsis. J Am Coll Surg 1998;187:321-9.
4. Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002;30 (5 Suppl):S302-12.
5. Bick RL, Arun B, Frenkel EP. Disseminated intravascular coagulation: clinical and pathophysiological mechanisms and manifestations. Haemostasis 1999;29:111-34.
6. Micek ST, Shah RA, Kollef MH. Management of severe sepsis: integration of multiple pharmacologic interventions. Pharmacotherapy 2003;23:1486-96.
7. Jimenez MF, Marshall JC. International Sepsis Forum. Source control in the management of sepsis. Intensive Care Med 2001; 27 (Suppl 1):S49-62.
8. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
9. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
10. Bernard G. International Sepsis Forum. The International Sepsis Forum's controversies in sepsis: corticosteroids should not be routinely used to treat septic shock. Crit Care 2002;6: 384-6.
11. Anonymous. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342: 1301-8.
12. Bellomo R, Farmer M, Wright C, Parkin G, Boyce N. Treatment of sepsis-associated severe acute renal failure with continuous hemodiafiltration: clinical experience and comparison with conventional dialysis. Blood Purif 1995;13:246-54.
13. Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med 2001;9:2264-70.
14. van den Berghe G, Wouters P, Weckers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
15. Corrigan JJ, Jr, Ray WL, May N. Changes in the blood coagulation system associated with septicemia. N Engl J Med 1968;279:851-6.
16. Lasch HG, Krecke HJ, Rodriguez-Erdmann F, Sessner HH, Schuetterle G. Consumption coagulopathies (pathogenesis and therapy). Folia Haematol (Frankf) 1961;6:325-30.
17. Muller-Berghaus G, ten Care H, Levi M. Disseminated intravascular coagulation: clinical spectrum and established as well as new diagnostic approaches. Thromb Haemost 1999;82:706-12.
18. Bick RL. Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis, and management: guidelines for care. Clin Appl Thromb Hemost 2002;8;1-31.
19. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000;28 (9 Suppl):S31-3.
20. Creasey AA, Reinhart K. Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med. 2001;29 (7 Suppl): S126-9.
21. Park CT, Creasey AA, Wright SD. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 1997; 89:4268-74.
22. Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002;30:1729-34.
23. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29:2081-9.
24. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-47.
25. Römisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002;13:657-70.
26. Nielsen JD. The effect of antithrombin on the systemic inflammatory response in disseminated intravascular coagulation. Blood Coagul Fibrinolysis 1998;9 (Suppl 3):S11-5.
27. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost 1998;24:27-32.
28. Wiedermann CJ, Römisch J. The anti-inflammatory actions of antithrombin - a review. Acta Med Austriaca 2002;29:89-92.
29. Dunzendorfer S, Kaneider N, Rabensteiner A, Meierhofer C, Reinisch C, Römisch J, et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 2001;97:1079-85.
30. Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun 2001;287:42-6.
31. Kaneider NC, Forster E, Mosheimer B, Sturn DH, Wiedermann CJ. Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost 2003;90:1150-7.
32. Kaneider NC, Reinisch CM, Dunzendorfer S, Römisch J, Wiedermann CJ. Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci 2002;115:227-36.
33. Souter PJ, Thomas S, Hubbard AR, Poole S, Römisch J, Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001;29:134-9.
34. Oelschlager C, Romisch J, Staubitz A, Stauss H, Leithauser B, Tillmanns H, et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002;99:4015-20.
35. Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 1998;10: 90-6.
36. Massignon D, Lepape A, Bienvenu J, Barbier Y, Boileau C, Coeur P. Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state. Haemostasis 1994;24: 36-48.
37. Pettila V, Hynninen M, Takkunen O, Kuusela P, Valtonen M. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 2002;28: 1220-5.
38. Mavrommatis AC, Theodoridis T, Economou M, Kotanidou A, El Ali M, Christopoulou-Kokkinou V, et al. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Intensive Care Med 2001;27:1853-9.
39. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996;88:881-6.
40. de Jonge E, Levi M, Stoutenbeek CP, van Deventer SJ. Current drug treatment strategies for disseminated intravascular coagulation. Drugs 1998;55:767-77.
41. Blauhut B, Kramar H, Vinazzer H, Bergmann H. Replacement of antithrombin III in shock and DIC: a randomized study. Thromb Res 1985;39:81-9.
42. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882-8.
43. Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998;24:336-42.
44. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998;24:663-72.
45. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286:1869-78.
46. DePalo V, Kessler C, Opal SM. Success or failure in phase III sepsis trials: Comparisons between the drotrecogin alpfa (activated) and antithrombin III clinical trials. Adv Sepsis 2001;1:114-24.
47. Opal SM. Clinical trial design and outcomes in patients with severe sepsis. Shock 2003;20:295-302.
48. Ettingshausen CE, Veldmann A, Beeg T, Schneider W, Jager G, Kreuz W. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 1999;25:537-41.
49. Muller FM, Ehrenthal W, Hafner G, Schranz D. Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Eur J Pediatr 1996;155:20-5.
50. Rintala E, Kauppila M, Seppala OP, Voipio-Pulkki LM, Pettila V, Rasi V, et al. Protein C replacement in sepsis-associated purpura fulminans. Crit Care Med 2000;28:2373-8.
51. Vaccarella G, Pelella R. Replacement treatment with protein C in an 18-year-old man with meningococcal sepsis and purpura fulminans. Minerva Anestesiol 2003;69:691-5.
52. de Kleijn ED, de Groot R, Hack CE, Mulder PG, Engl W, Moritz B, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003; 31:1839-47.
53. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345:408-16.
54. Schwarz HP, Ehrlich HJ. Activated protein C: more effective than nonactivated protein C? Crit Care Med 2003;31:1597.
55. Hesselvik JF, Malm J, Dahlback B, Blomback M, Protein C. protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 1991;65:126-9.
56. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001;120:915-22.
57. Grinnell BW, Joyce D. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med 2001;29 (7 Suppl):S53-61.
58. Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003;102: 1499-505.
59. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276:11199-203.
60. Hancock WW, Grey ST, Hau L, Akalin E, Orthner C, Sayegh MH, et al. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 1995;60:1525-32.
61. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002;296:1880-2.
62. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003;90:642-53.
63. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE, Jr, Russell JA, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29:2051-9.
64. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
65. Ott A, Verbrugh HA. Recombinant human activated protein C for severe sepsis. N Engl J Med 2001;345:220.
66. Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003;7:155-63.
67. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002; 30 (5 Suppl):S325-31.
68. Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Kaneider NC, Dunzendorfer S, et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002;88:242-52.
69. Rublee D, Opal SM, Schramm W, Keinecke HO, Knaub S. Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. Crit Care 2002;6:349-56.
70. Eichacker PQ, Natanson C. Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit Care Med 2003;31 (1 Suppl):S94-6.
71. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002;347:1027-30.
72. Carlet J. Drotrecogin alfa (activated) administration: too many subgroups. Crit Care Med 2003;31:2564.
73. Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med 2002;347:1030-4.
74. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003;29:894-903.
75. Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, et al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med 2003;31:2291-301.
76. Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003;31:12-9.
77. Ely EW, Angus DC, Williams MD, Bates B, Qualy R, Bernard GR. Drotrecogin alfa (activated) treatment of older patients with severe sepsis. Clin Infect Dis 2003b;37:187-95.
78. Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003;37:50-8.
79. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamat HH, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003;31: 834-40.
80. Laterre PF, Wittebole X. Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis - practical aspects at the bedside and patient identification. Crit Care 2003;7:445-50.
81. Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003;102:2093-8.
82. Taylor F, Jr. Comment on "Drotrecogin Alfa (activated) (recombinant human protein C, rhAPC) reduces host coagulopathy response in patients with severe sepsis". Thromb Haemost 2003;90:560-1.
83. Angus DC, Laterre PF, Helterbrand J, Ball D, Garg R, Bernard GR. The effect of drotrecogin alpha (activated) on long-term survival after severe sepsis. Chest 2003;122 (Suppl): S144.
84. Ziegler EJ, Fisher CJ, Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324: 429-36.
85. Anonymous. Drotrecogin alfa: new preparation. For some cases of severe sepsis? Prescrire Int 2003;12:55-7.